原发性肝癌患者的PEBP4和CD146表达与肝动脉化学治疗栓塞术疗效的关系及临床意义  

Relationship between expression of PEBP4 and CD146 in patients with primary liver cancer and efficacy of transcatheter hepatic arterial chemoembolization and its clinical significance

作　　者：徐元丰[1] 沈涛[1] 宋蒨[1] 巢浩强 XU Yuanfeng;SHEN Tao;SONG Qian;CHAO Haoqiang(Departmentof Interventional Vascular,Wujin People′s Hospital Affiliated to Jiangsu University,Wujin Clinical College Affiliatedto Xuzhou Medical College,Changzhou 213000,China)

机构地区：[1]江苏大学附属武进人民医院徐州医科大学武进临床学院介入血管科

出　　处：《国际消化病杂志》2019年第6期399-404,共6页International Journal of Digestive Diseases

摘　　要：目的探讨原发性肝癌(PHC)患者的磷脂酰乙醇胺结合蛋白4(PEBP4)和CD146表达与肝动脉化学治疗栓塞(TACE)术疗效的关系及临床意义。方法选择江苏大学附属武进人民医院接受TACE术治疗的80例PHC患者作为研究对象,采用免疫组织化学法检测肝癌组织中PEBP4、CD146的表达情况,并分析PHC患者的EBP4、CD146表达与其临床病理特征、预后及TACE术疗效之间的相关性。结果患者的PEBP4高表达率为32.50%(26/80),低表达率为67.50%(54/80);CD146高表达率为37.50%(30/80),低表达率为62.50%(50/80)。PEBP4高表达组更多见于低分化、浸润深度更深、Ⅲ~Ⅳ期的患者,更易发生淋巴结转移。CD146高表达组更多见于低分化、合并血管内癌栓、浸润深度更深的患者,更易发生淋巴结转移。PEBP4低表达组患者的2年生存率为53.70%(29/54),高于PEBP4高表达组[38.46%(10/26)],差异有统计学意义(χ^2=7.179,P=0.007)。CD146低表达组的2年生存率为62.00%(31/50),高于CD146高表达组[46.67%(14/30)],差异有统计学意义(χ^2=5.443,P=0.020)。单因素和多因素分析显示,PEBP4、CD146为影响PHC患者生存时间的独立因素(P<0.05)。PEBP4和CD146低表达组经TACE术治疗的临床有效率均显著高于高表达组(P均<0.05)。结论PHC患者的PEBP4、CD146表达状态与其临床病理特征具有相关性,且PEBP4、CD146是PHC患者预后的独立影响因素。PEBP4和CD146低表达的患者经TACE术治疗效果更好。Objective This paper aimed to investigate the relationship between the expression of phosphatidylethanolamine binding protein 4(PEBP4)and CD146 and the efficacy of transcatheter hepatic arterial chemoembolization(TACE)in patients with primary hepatic carcinoma(PHC)and its clinical significance.Methods Eighty patients with PHC who received TACE treatment in Wujin People′s Hospital Affiliated to Jiangsu University were selected as the research subjects.The expression of PEBP4 and CD146 in liver cancer tissues was detected by immunohistochemistry.The correlations between the expressions of EBP4 and CD146,and their clinicopathological features,prognosis,and efficacy of TACE in patients with PHC were analyzed.Results The high expression rate of PEBP4 in patients was 32.50%(26/80)while the low expression rate was 67.50%(54/80).The high expression rate of CD146 was 37.50%(30/80)whereas the low expression rate was 62.50%(50/80).Besides,the PEBP4 high expression group was more common in patients with low differentiation,deeper infiltration depth,stage Ⅲ~Ⅳ,and more prone to lymph node metastasis.However,the CD146 high expression group was more common in patients with low differentiation,intravascular tumor thrombus,and deeper invasion,and was more prone to lymph node metastasis.In addition,the 2-year survival rate of patients with low PEBP4 expression was 53.70%(29/54),which was higher than that of PEBP4 high expression(38.46%(10/26)),and the difference was statistically significant(χ^2=7.179,P=0.007).Moreover,the 2-year survival rate of the CD146 low expression group was 62.00%(31/50),which was higher than the CD146 high expression group(46.67%(14/30)),and the difference was statistically significant(χ^2=5.443,P=0.020).Furthermore,univariate and multivariate analysis showed that PEBP4 and CD146 were independent factors affecting the survival time of patients with PHC(P<0.05).The clinical response rate of PEBP4 and CD146 low expression group after TACE treatment was significantly higher than that of high expression

关 键 词：磷脂酰乙醇胺结合蛋白4 CD146 原发性肝癌 肝动脉化学治疗栓塞术 临床意义 

分 类 号：R73[医药卫生—肿瘤]